Develops self-adjuvanting, multi-antigen vaccine candidates using a proprietary platform to target antimicrobial-resistant pathogens. This approach addresses the growing threat of untreatable microbial infections by providing preventive solutions with the potential for broad efficacy and reduced reliance on traditional adjuvants.
Funding
$40.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AIFounders
Product
Problem
The rise of antimicrobial-resistant (AMR) pathogens poses a significant threat to global health, as traditional treatments become ineffective against microbial infections. Current vaccine technologies often require external adjuvants, which can have limitations in terms of efficacy and safety.
Solution
LimmaTech Biologics is developing a novel approach to combat AMR pathogens through self-adjuvanting, multi-antigen vaccine candidates. Their proprietary vaccine platform aims to prevent increasingly untreatable microbial infections by incorporating both the antigen and adjuvant within a single molecule. This technology seeks to elicit a broad and robust immune response without the need for traditional adjuvants, potentially improving vaccine efficacy and reducing reliance on conventional methods. The company leverages its expertise in vaccine technology and clinical candidate development to generate protective solutions against a range of AMR threats.
Target Audience
The primary target audience includes individuals at risk of infection from antimicrobial-resistant pathogens, as well as public health organizations and governments seeking to combat the spread of AMR.
Features
- Proprietary self-adjuvanting technology that combines antigen and adjuvant functionalities
- Multi-antigen approach to target multiple strains or serotypes of a pathogen
- Vaccine candidates designed to elicit broad and robust immune responses
- Focus on preventing infections caused by antimicrobial-resistant bacteria
- Pipeline of vaccine candidates targeting various AMR pathogens